A prospective trial of gastrointestinal cancer patients showed the feasibility of preemptive genetic testing for DPYD/UGT1A1 variants associated with increased chemotherapy toxicity. Genotype-guided ...
National clinical guidelines don’t mention screening cancer patients for DPYD gene variants, but hospital pharmacy leaders are forging ahead with the patient safety practice, the American Society of ...
Aranscia® solutions help oncologists comply with new FDA warning label requiring DPYD genetic testing in patients receiving select chemotherapies HOUSTON, Oct. 16, 2025 /PRNewswire/ -- Oncologists and ...
Please provide your email address to receive an email when new articles are posted on . Genetic testing can be accomplished for most patients with gastrointestinal cancer prior to starting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results